1. Introduction {#s0025}
===============

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inheritable cardiomyopathy pathologically characterized by fibrofatty infiltrations in the myocardium leading to thinning of the wall and aneurysms. Clinical presentation is mainly due to ventricular arrhythmias and may include palpitations, syncope, and sudden cardiac death ([@bb0005]). Diagnosis is based on Task Force criteria ([@bb0010]), which encompass functional and anatomical characteristics of the right ventricle, electrical abnormalities, family history, and genetic information. The original Task Force criteria were published in 1994, and in 2010 revised criteria were published ([@bb0010]).

To this date ARVC has been associated with mutations in five desmosomal (*DSC2*, *DSG2*, *DSP*, *JUP*, and *PKP2*) and five non-desmosomal genes (*TGFβ3*, *RYR2*, *TMEM43*, *DES*, and *TTN*) ([@bb0005], [@bb0015], [@bb0020]). Although ten genes have been associated with ARVC, these only account for approximately 40% of the patients with identifiable mutations ([@bb0025], [@bb0030]) underlining the genetic heterogeneity of the disease.

In the present study we aimed at investigating the involvement of six candidate genes which have not previously been investigated in the pathogenesis of ARVC: *SCN1B*-*SCN4B* (Sodium channel, voltage gated, type I-IV, beta), encoding β-subunits for the cardiac sodium channel, *FHL1* (Four and a half LIM domains 1), encoding a member of the four-and-a-half LIM only protein family, and *LMNA* (Lamin A/C), encoding a nuclear envelope protein. All are highly expressed in the heart and are known to interact with ARVC-associated genes. They have also been associated with heritable arrhythmia syndromes and/or cardiomyopathy ([@bb0035], [@bb0040], [@bb0045]).

2. Methods {#s0030}
==========

2.1. Study subjects {#s0045}
-------------------

The study comprised 65 unrelated patients recruited from Rigshospitalet, Copenhagen University Hospital, Denmark. All patients were of Northern European descent. The clinical characteristics of the study population have previously been published ([@bb0025]). All patients have previously been screened for mutations in the known ARVC-related genes (*DSC2*, *DSG2*, *DSP*, *JUP*, *PKP2*, *TGFb3*, and *TMEM43*) and mutations were identified in 36% of patients fulfilling the 1994 Task Force criteria ([@bb0025], [@bb0050]). Since compound inheritance has been described ([@bb0030]) we chose not to exclude patients with known mutations from further screening. The study was approved by the local ethics committee, followed the Helsinki II declaration, and all subjects gave written informed consent before inclusion.

2.2. Genetic screening {#s0050}
----------------------

Genomic DNA was isolated from blood samples using the QIAamp DNA Blood Mini Kit (QIAGEN, Hilden, Germany). The coding sequences and splice sites of *SCN1B* ([NM_001037.3](ncbi-n:NM_001037.3), [NM_199037.2](ncbi-n:NM_199037.2)), *SCN2B* ([NM_004588.4](ncbi-n:NM_004588.4)), *SCN3B* ([NM_018400.3](ncbi-n:NM_018400.3)), *SCN4B* ([NM_174934.2](ncbi-n:NM_174934.2)), *FHL1* ([NM_001449](ncbi-n:NM_001449), [NM_001159700](ncbi-n:NM_001159700), [NM_001159704](ncbi-n:NM_001159704), [NM_001167819](ncbi-n:NM_001167819), [NM_001159702](ncbi-n:NM_001159702), [NM_001159703](ncbi-n:NM_001159703)), and *LMNA* ([NM_005572](ncbi-n:NM_005572), [NM_0170707.2](ncbi-n:NM_0170707.2)), corresponding to a total of 38 exons, were amplified with intronic primers and bidirectionally sequenced using Big Dye chain-termination chemistry (DNA analyzer 3730, Applied Biosystems, CA, USA). Some amplicons were prescreened with a LightScanner high-resolution melting curve analysis system (Idaho Technology, UT, USA). All fragments with an abnormal melting profile were sequenced. Primers and PCR conditions are available on request.

3. Results {#s0035}
==========

3.1. Study cohort {#s0055}
-----------------

A total of 65 (38 men) patients were included in the study. 55 of the patients fulfilled 1994 Task Force criteria for ARVC: ≥ two major criteria (*n* = 15), one major and ≥ two minor criteria (*n* = 36), and four minor criteria (*n* = 4). Ten patients had some ARVC characteristics but did not fulfill the criteria: one major and one minor criterion (*n* = 5), three minor criteria (*n* = 4), and two minor criteria (*n* = 1).

3.2. Genetic screening {#s0060}
----------------------

The variant analysis identified a total of 28 sequence variants: Seven in *SCN1B*, three in *SCN2B*, two in *SCN3B*, two in *SCN4B*, four in *FHL1*, and ten in *LMNA*. The identified variants are listed in [Table 1](#t0005){ref-type="table"}. Three of the variants were novel. All novel variants were positioned in flanking introns and did not affect a canonical splice site. One non-synonymous variant was identified (*FHL1* p.D275N). No disease-causing mutations were identified.

4. Discussion {#s0040}
=============

This study is the first comprehensive attempt to associate ARVC with genetic variation in the accessory subunits of the cardiac Na~v~1,5 channel, *FHL1*, and *LMNA*. Screening of these genes, representing 38 exons, revealed no disease-causing mutations and these genes are therefore unlikely to be common causes of ARVC.

The channels carrying the cardiac sodium current (Na~v~1.5) is composed of an α-subunit, encoded by *SCN5A*, and two of the four β-subunits ([@bb0035]). The β subunits (β1--β4), encoded by *SCN1B*-*4B*, are multifunctional and members of the immunoglobulin superfamily. Some of their functions may be independent of the α-subunit ([@bb0035]) and several studies have demonstrated that β1 and β2 both play important roles in homophilic and heterophilic cell adhesion and function as cell adhesion molecules ([@bb0035], [@bb0055]). A recent study demonstrated a physical and functional interaction between Na~v~1.5 and the ARVC-associated gene *PKP2* at the intercalated disc and an altered sodium current after knockdown of *PKP2* ([@bb0060]). In addition, [@bb0065] showed that these alterations of the sodium current complex lead to an increased susceptibility to arrhythmias due to reentrant activity, even without anatomical obstacles. Furthermore, it has been demonstrated that 16% of the ARVC patients exhibit inducible coved-type ST elevations in right precordial leads ([@bb0070]), an ECG finding usually characteristic of Brugada Syndrome, and that mutations affecting Na~v~1.5 are prevalent in Brugada syndrome patients with structural heart abnormalities resembling ARVC ([@bb0075], [@bb0080]). Both *SCN1B* and *SCN3B* have recently been associated with Brugada Syndrome ([@bb0085]). These findings thus suggest that the sodium current complex could play a role in the pathogenesis of ARVC. A variety of other diseases have also been associated with mutations in *SCN1B*-*4B*, including cardiac arrhythmia, cancer, and neurological diseases ([@bb0035], [@bb0055], [@bb0090]).

The *FHL1* gene, located on the X chromosome, is characterized by a half LIM domain in the N-terminus and four following complete LIM domains. The protein is localized both in the cytosol and the nucleus and has several functions including transcription regulation, cell signaling, and sarcomere assembly ([@bb0040]). *FHL1* interacts with *TTN* recently associated with ARVC4 ([@bb0015], [@bb0040]). A wide variety of human muscle diseases including non-compaction, hypertrophic and dilated cardiomyopathies, have been associated with *FHL1* mutations ([@bb0040]). In our study the non-synonymous variant *FHL1* p.D275N was present in one patient. The variant affects an unconserved residue located in the C-terminus of the *FHL1* peptide. The variant has previously been described in control populations ([@bb0095]) and was present in 31 out of 1669 alleles of American/European descent in the NHLBI GO Exome Sequencing Project ([@bb0100]). We therefore consider it to be a polymorphism.

The *LMNA* gene, encoding the intermediate filament proteins lamin A and C, plays a role in maintaining the structural integrity of the inner nuclear membrane, in gene expression, and in organization of chromatin ([@bb0045]). The lamins interact with several proteins, including TMEM43, associated with ARVC5 ([@bb0005], [@bb0105]). The ARVC-genes *TMEM43* and *JUP* are believed to cause dysregulation of the adipogenic pathway regulated by PPAR-γ, resulting in adipogenesis, fibrogenesis and myocyte apoptosis ([@bb0110]), and may explain the fibrofatty replacement in the myocardium characteristic of ARVC. Also *LMNA* have been suggested to affect PPAR-γ. ([@bb0115]). Mutations in *LMNA* have been associated with numerous extracardiac disorders, conduction defects, ventricular arrhythmia, and dilated cardiomyopathy ([@bb0045]). Dilated cardiomyopathy may mimic ARVC and a predominantly left-sided form of ARVC is becoming increasingly recognized ([@bb0120]) making *LMNA* a plausible candidate gene for ARVC.

This study has the following limitations: We only analyzed the coding regions of *SCN1B*-*4B*, *FHL1*, and *LMNA*, and the possibility of variants occurring in other regions of the genes cannot be excluded. Our study cohort has a limited size and all patients were of Northern European descent, thus we cannot exclude the possibility of different results in cohorts of different ethnicity. The diagnosis of our cohort is based on the 1994 Task Force criteria. We were not able to apply the revised criteria published in 2010 to our cohort, due to lack of necessary clinical data, e.g. all myocardial biopsies are obtained from the septum.

In conclusion, we found no disease-causing mutations in ARVC patients within the *SCN1B*-*4B*, *FHL1*, and *LMNA* genes. The present study is to our knowledge the first attempt to associate genetic variation in these genes with ARVC. Our results indicate that these six genes are not common causes of ARVC.
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Identified sequence variants.

  Gene            Variant        Exon/intron   Amino acid   Minor allele   MAF[a](#tf0005){ref-type="table-fn"}   dbSNP
  --------------- -------------- ------------- ------------ -------------- -------------------------------------- ------------
  *SCN1B*         c.40+15G\>T    Intron                     T              0.238                                  rs72556351
  c.448+181T\>C   Intron                       C            0.423          rs55742440                             
  c.448+296C\>A   Intron                       A            0.169          rs67701503                             
  c.448+301G\>C   Intron                       C            0.169          rs67486287                             
  c.860T\>C       Exon           p.I167I       C            0.046          rs16969930                             
  c.591-25T\>G    Intron                       G            0.008          rs28365107                             
  c.591-14C\>A    Intron                       A            0.008          rs28365109                             
  *SCN2B*         c.70+32G\>A    Intron                     A              0.023                                  --
  c.449-12C\>A    Intron                       A            0.454          rs8192613                              
  c.648+38C\>T    Intron                       T            0.092          rs8192614                              
  *SCN3B*         c.438C\>T      Exon          p.T146T      T              0.054                                  rs1275085
  c.445+37T\>G    Intron                       G            0.008          --                                     
  *SCN4B*         c.174C\>T      Exon          p.C58C       T              0.046                                  rs45539032
  c.639C\>T       Exon           p.N213N       T            0.023          rs72544155                             
  *FHL1*          c.688+37G\>A   Intron                     A              0.008                                  --
  c.689-8C\>T     Intron                       T            0.546          rs2076705                              
  c.689-13C\>T    Intron                       C            0.031          rs11798700                             
  c.823G\>A       Exon           p.D275N       A            0.008          --                                     
  *LMNA*          c.612G\>A      Exon          p.L204L      A              0.015                                  rs12117552
  c.369+56G\>T    Intron                       T            0.031          rs11264442                             
  c.639+73C\>T    Intron                       T            0.031          rs11264443                             
  c.640-52C\>T    Intron                       T            0.008          rs41314033                             
  c.861T\>C       Exon           p.A287A       C            0.054          rs538089                               
  c.937-83G\>T    Intron                       T            0.054          rs80356810                             
  c.1157+16G\>A   Intron                       A            0.054          rs534807                               
  c.1338T\>C      Exon           p.D446D       C            0.054          rs505058                               
  c.1489-41C\>T   Intron                       T            0.054          rs553016                               
  c.1698C\>T      Exon           p.H566H       T            0.231          rs4641                                 

Minor allele frequency in the 130 patient alleles tested.
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